Open
Do investigational compounds improve lipids more than other treatments?
Also asked versus placebo.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Unlikely. So far, the results disagree.
NoUnsureYes
- Belief
- 0.00 (range 0.00–0.55)
- Trials for
- 0
- Trials against
- 2
- Inconclusive
- 0
Already under way
No registered trial that could settle this is recruiting or active.
The evidence so far
- Registered trials
- 75
- With posted results
- 21
- Published papers
- 3
Of 195 decided analyses: 84 favor investigational compounds, 44 find no difference, 67 favor the comparator.
Papers
- Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.Meta-analysis / systematic review · 2015
- Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment.Meta-analysis / systematic review · 2013
- Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.Trial report · 2008
Trials
- A Randomized, Placebo Controlled, Repeat Dose, Double Blind (Sponsor Unblind) Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes PatientsNCT02202161 · 72 posted results
- A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK0524B Versus Atorvastatin in Patients With Mixed HyperlipidemiaNCT00289900 · 40 posted results
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With AtorvastatinNCT01218204 · 80 posted results
- A Multicenter, Randomized, Double-Blind, "Crossover" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK-0524A + Simvastatin Coadministration in Patients With Primary Hypercholesterolemia and Mixed DyslipidemiaNCT00479882 · 8 posted results
- Dose Response and Safety of an Oral PCSK9i, NNC0385-0434, in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk on Maximally Tolerated Statin Dose and Other Lipid-lowering Therapy Requiring Further LDL-C ReductionNCT04992065 · 14 posted results
- A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic ControlNCT00868790 · 4 posted results
- A Phase 2, Double-blind, Placebo-controlled, Randomized Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On High Doses Of Atorvastatin, Rosuvastatin Or Simvastatin.NCT01342211 · 44 posted results
- A Phase 2 Dose Response Study of LY2484595 in Japanese SubjectsNCT01375075 · 14 posted results